RXO opened higher at $28.32, compared with its previous close of $28.14. In the last trading session, the stock traded between $28.24 and $28.54. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in RXO is now worth
$ 148.86
Giving a profit of
$ 48.86 (48.86%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 12 Analysts
Buy
25%
Hold
75%
Sell
0%
Markets Today
Today's Change
+$0.23 (+0.82%)
Day High
$28.54
Day Low
$28.24
Day Open
$28.32
Prev Close
$28.14
Volume
21,09,948
1W Return
-0.07%
1M Return
-1.15%
3M Return
32.18%
6M Return
37.06%
1Y Return
132.94%
Fundamentals
Market Cap ($ Mn)
4,680
PE Ratio
-
PB Ratio
2.40
PEG Ratio
-
ROE
-6.32%
ROCE
-3.47%
EPS (TTM)
$0.02
Investment Returns
1 Week
-0.07%
1 Month
-1.15%
3 Months
32.18%
6 Months
37.06%
9 Months
73.74%
Financials
Quarterly
All values in $ Mn
1.4K
Jun 25
1.4K
Sep 25
1.5K
Dec 25
1.4K
Mar 26
1.8K
Jun 26
1.9K
Sep 26
Updates
5Nov
UBS raises RXO price target to $30.25, maintains neutral rating
UBS raises RXO price target to $30.25 from $23. Analyst Thomas Wadewitz maintains Neutral rating. Target increase of $7.25 reflects updated projections. Rating remains Neutral despite higher valuation.
8 days ago
6Oct
Kahn Swick & Foti probes RXO sale to C.H. Robinson for fair value
Kahn Swick & Foti, LLC joins Halper Sadeh and Ademi LLP in investigating the proposed sale of RXO Inc to C.H. Robinson. The deal offers RXO shareholders $17.25 in cash and 0.0856 shares of C.H. Robinson stock per share, valuing RXO at approximately $5.8 billion. Law firms are scrutinizing whether the exchange ratio reflects true market value and if board duties were fulfilled during negotiations.
Adjusted EBITDA reached $40 million, exceeding the high end of prior guidance. Truckload spot mix increased to 42%, driving an 11% sequential rise in gross profit per load. Brokerage revenue grew 32% YoY to $1.3 billion, while Last Mile stops rose 3%. Q3 adjusted EBITDA guided between $35 million and $45 million amid mixed segment trends.
RXO delivered a strong second-quarter performance, reporting adjusted EPS of $0.06 against an estimate of $0.03, a 100 percent beat. Sales totaled $1.774 billion, surpassing the $1.603 billion consensus by 10.68 percent and rising 25.02 percent year-over-year from $1.419 billion. The results reflect significant operational leverage and demand strength.
3mo ago
17Jul
Goldman Sachs maintains Neutral on RXO, raises target to $20
Goldman Sachs analyst Jordan Alliger maintains a Neutral rating on RXO and raises the price target from $18 to $20.
3mo ago
15Jul
Truist Securities maintains Buy on RXO, raises target to $30
Truist Securities analyst Lucas Servera maintained a Buy rating on RXO and raised the price target to $30 from $26, indicating a more optimistic outlook.
